MERIDIAN
M&AHealthcareRUMOURED

Johnson & Johnson in Talks to Acquire Ollin Biosciences for Up to $3.4 Billion

Photo via Pexels
Value
$3.4Bn
Acquirer
Johnson & Johnson
Target
Ollin Biosciences

Johnson & Johnson is looking to buy eye disease biotech Ollin Biosciences for up to $3.4bn. The potential acquisition is the latest transaction in a wave of deals within the biotechnology sector.

✦ Meridian Analysis
Johnson & Johnson is reported to be in talks to acquire eye‑disease biotech Ollin Biosciences for up to $3.4 billion, a transaction that remains at the rumour stage. In this potential deal Johnson & Johnson would act as the strategic buyer, while Ollin Biosciences is the target. The mechanics would be a typical M&A purchase, but the exact structure—whether a share purchase, asset sale or a combination of cash and equity—has not been disclosed. No information on financing terms, advisory banks or any regulatory clearances has been provided, and the parties have not confirmed a definitive agreement. Deal professionals will be watching for the announcement of a definitive agreement, which should reveal the purchase price breakdown, any earn‑out components and the financing package. Information on the advisers involved, antitrust or other regulatory approvals required, and the expected closing timetable has not been disclosed and will be crucial to assess the transaction’s impact on both companies and the broader biotech M&A environment.
Read the original at Financial Times →2026-11-15North America
The Meridian Weekly

The week's largest deals and the Iberian ones, every Monday. Free.

MORE DEALS ON MERIDIAN ->